Table 2.
HIV-1 R5 and X4 Tat amino acid usage
| Position | AA | R5 count | R5 % | X4 count | X4 % |
|---|---|---|---|---|---|
| 7 | K | 95 | 0.19 | 0 | 0.00 |
| N | 12 | 0.02 | 2 | 0.06 | |
| S | 115 | 0.23 | 2 | 0.06 | |
| R | 281 | 0.56 | 27 | 0.87 | |
| 23 | N | 230 | 0.46 | 5 | 0.16 |
| T | 274 | 0.54 | 26 | 0.84 | |
| 57 | A | 5 | 0.01 | 3 | 0.10 |
| R | 400 | 0.79 | 28 | 0.90 | |
| T | 89 | 0.18 | 0 | 0.00 | |
| 60 | E | 87 | 0.17 | 1 | 0.03 |
| D | 7 | 0.01 | 2 | 0.06 | |
| K | 30 | 0.06 | 0 | 0.00 | |
| Q | 242 | 0.48 | 22 | 0.71 | |
| P | 35 | 0.07 | 5 | 0.16 | |
| R | 86 | 0.17 | 0 | 0.00 |
The raw counts and relative abundance value of amino acids present in statistically divergent Tat positions for both the R5 and X4 sequence groups (7, 23, 57 and 60)